Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

October 31, 2008

Conditions
Cocaine DependenceOpioid Dependency
Interventions
DRUG

levetiracetam

The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.

DRUG

Placebo

Trial Locations (1)

06516

VA CT Healthcare System, West Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER

NCT00577005 - Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients | Biotech Hunter | Biotech Hunter